Janet Pope

Active 1991–2025

184
Papers
34,805
Citations
96
h-index
177
i10-index

Citations

Citations per year for Janet Pope1982: 4 citations1985: 3 citations1986: 1 citations1988: 1 citations1990: 1 citations1991: 1 citations1992: 1 citations1994: 4 citations1995: 2 citations1996: 4 citations1997: 3 citations1998: 18 citations1999: 21 citations2000: 23 citations2001: 23 citations2002: 25 citations2003: 31 citations2004: 18 citations2005: 42 citations2006: 41 citations2007: 51 citations2008: 54 citations2009: 78 citations2010: 92 citations2011: 79 citations2012: 107 citations2013: 125 citations2014: 155 citations2015: 204 citations2016: 248 citations2017: 270 citations2018: 193 citations2019: 971 citations2020: 1,165 citations2021: 1,371 citations2022: 1,170 citations2023: 840 citations2024: 1,419 citations2025: 663 citations2026: 20 citations1983–1984: no citations, so these years are not shown1987: no citations, so this year is not shown1989: no citations, so this year is not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,492 citing papers, 17.4% of this breakdownUnited Kingdom: 1,197 citing papers, 8.4% of this breakdownChina: 1,035 citing papers, 7.2% of this breakdownItaly: 977 citing papers, 6.8% of this breakdownGermany: 737 citing papers, 5.2% of this breakdownCanada: 698 citing papers, 4.9% of this breakdownFrance: 682 citing papers, 4.8% of this breakdownNetherlands: 515 citing papers, 3.6% of this breakdownJapan: 493 citing papers, 3.5% of this breakdownSpain: 413 citing papers, 2.9% of this breakdownSwitzerland: 392 citing papers, 2.7% of this breakdownAustralia: 390 citing papers, 2.7% of this breakdown
0%17.4%Other 29.9%

Fields

  • Medicine82.8%
  • Biochemistry, Genetics and Molecular Biology6.7%
  • Immunology and Microbiology5.8%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Agricultural and Biological Sciences0.7%
  • Neuroscience0.6%
  • Other2.5%

Topics

  • Rheumatoid Arthritis Research and Therapies10.4%
  • Systemic Sclerosis and Related Diseases8.8%
  • Systemic Lupus Erythematosus Research6.4%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis3.6%
  • Spondyloarthritis Studies and Treatments3.2%
  • Inflammatory Myopathies and Dermatomyositis2.9%
  • Other64.7%

Coauthors

All papers

Open in search
  1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo Mysler, Peter Nash, Gyula Poór, Gorica Ristić, Felice Rivellese, Andrea Rubbert‐Roth, Hendrik Schulze‐Koops, Nikolay Stoilov, Anja Strangfeld, Annette H M van der Helm–van Mil, Elsa van Duuren, T. P. M. Vliet Vlieland, René Westhovens, Désirée van der Heijde - Annals of the Rheumatic Diseases 2022 cited by 1,788

  2. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David H. Collier, Mary Ellen Csuka, Barri J. Fessler, Serena Guiducci, Ariane L. Herrick, Vivien Hsu, Sergio A. Jiménez, Bashar Kahaleh, Peter A. Merkel, S. Sierakowski, Richard M. Silver, Robert W. Simms, John Varga, Janet Pope - Annals of the Rheumatic Diseases 2013 cited by 3,406

  3. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde - Annals of the Rheumatic Diseases 2020 cited by 2,766

  4. Novel treatment strategies in rheumatoid arthritis

    Authors: , - The Lancet 2017 cited by 1,053

  5. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mette Mogensen, Anne Braae Olesen, Yannick Allanore, J. Henes, Ulf Müller‐Ladner, Gabriela Riemekasten, Alla Skapenko, Panayiotis G. Vlachoyiannopoulos, Emese Kiss, Tünde Minier, Lorenzo Beretta, Elisa Gremese, Marco Matucci‐Cerinic, Gabriele Valentini, Yoshihide Asano, Tatsuya Atsumi, Hironobu Ihn, Tomonori Ishii, Osamu Ishikawa, Masataka Kuwana, Yoshihito Shima, Hiroki Takahashi, Kazuhiko Takehara, Yoshiya Tanaka, Yoshioki Yamasaki, Loreta Bukauskienė, İrena Butrimienė, Gabriel Medrano Ramírez, César Ramos-Remus, Tatiana Sofía Rodríguez Reyna, Jeska de Vries‐Bouwstra, Jacob M. van Laar, Bogdan Batko, Sławomir Jeka, Eugeniusz J. Kucharz, Maria Majdan, Marzena Olesińska, Żaneta Smoleńska, José Delgado Alves, María José Santos, C. Mihai, Simona Rednic, Ivan Castellvi Barranco, Francisco Longo, C Simeόn Aznar, Patrícia Carreira, Oliver Distler, Ulrich A. Walker, Emma Derrett‐Smith, Bridget Griffiths, Neil D McKay, Christopher P. Denton, Jacob Aelion, Michael Borofsky, Roy Fleischmann, Joseph Z. Forstot, Daniel E. Furst, Suzanne Kafaja, Mahmuda Khan, Dinesh Khanna, Michael Kohen, Richard W. Martin, Fabian Mendoza-Ballesteros, Alireza Nami, Shirley Pang, Grissel Ríos, Robert W. Simms, Keith M. Sullivan, Virginia Steen - The Lancet Respiratory Medicine 2020 cited by 652

  6. Systemic sclerosis

    Authors: , , , , , , - Nature Reviews Disease Primers 2015 cited by 862

  7. State-of-the-art evidence in the treatment of systemic sclerosis

    Authors: , , , , , - Nature Reviews Rheumatology 2023 cited by 191

  8. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

    Authors: , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2015 cited by 890

  9. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 cited by 669

  10. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities

    Authors: , - Seminars in Arthritis and Rheumatism 2020 cited by 313

  11. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 168

  12. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 cited by 288

  13. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 139

  14. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

    Authors: , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2013 cited by 825

  15. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    Authors: , , , , , , , , , , , , , , , , , - Journal of Scleroderma and Related Disorders 2017 cited by 521

  16. Transancestral mapping and genetic load in systemic lupus erythematosus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey C. Edberg, Emõke Endreffy, Jorge Antonio Esquivel‐Valerio, Paul R. Fortin, Barry I. Freedman, Johan Frostegård, Mercedes García, Ignacio García‐De La Torre, Gary S. Gilkeson, Dafna D. Gladman, Iva Gunnarsson, Joel M. Guthridge, Jennifer L. Huggins, Judith A. James, Cees G. M. Kallenberg, Diane L. Kamen, David R. Karp, Kenneth M. Kaufman, Leah C. Kottyan, László Kovács, Helle Laustrup, Bernard Lauwerys, Quan‐Zhen Li, Marco A. Maradiaga‐Ceceña, Javier Martı́n, Joseph M. McCune, David R. McWilliams, Joan T. Merrill, Pedro C. Miranda, J. F. Moctezuma, Swapan K. Nath, Timothy B. Niewold, Lorena Orozco, Norberto Ortego‐Centeno, Michelle Petri, Christian A. Pineau, Bernardo A. Pons‐Estel, Janet Pope, Prithvi Raj, Rosalind Ramsey‐Goldman, John D. Reveille, Laurie Russell, José Mario Sabio, Carlos A. Aguilar‐Salinas, Hugo R. Scherbarth, R Scorza, Michael F. Seldin, Christopher Sjöwall, Elisabet Svenungsson, Susan D. Thompson, Sergio Toloza, Lennart Truedsson, Teresa Tusié‐Luna, Carlos Vasconcelos, Luis M. Vilá, Daniel J. Wallace, Michael H. Weisman, Joan Wither, Tushar Bhangale, Jorge R. Oksenberg, John D. Rioux, Peter K. Gregersen, Ann‐Christine Syvänen, Lars Rönnblom, Lindsey A. Criswell, Chaim O. Jacob, Kathy L. Sivils, Betty P. Tsao, Laura E. Schanberg, Timothy W. Behrens and 8 more - Nature Communications 2017 cited by 437

  17. Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

    Authors: , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2022 cited by 114

  18. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review

    Authors: , , , , , - Journal of Clinical Medicine 2021 cited by 109

  19. Mortality in systemic lupus erythematosus

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Y. St. Pierre, Ann E. Clarke, Rosalind Ramsey‐Goldman - Arthritis & Rheumatism 2006 cited by 1,187

  20. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

    Authors: , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 cited by 68

  21. Management of Fatigue in Rheumatoid Arthritis

    Authors: - RMD Open 2020 cited by 133

  22. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2016 cited by 234

  23. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yue Wang, Tammara Wood, Yannick Allanore, M. Matucci-Cerinic, Oliver Distler, Ora Singer, Erica Bush, David A. Fox, Daniel E. Furst - Arthritis & Rheumatology 2019 cited by 224

  24. A meta-analysis of the epidemiology of giant cell arteritis across time and space

    Authors: , , , - Arthritis Research & Therapy 2021 cited by 155